These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29745873)

  • 1. Do antimalarials protect against damage accrual in primary Sjögren's syndrome? Results from a Latin-American retrospective cohort.
    Hernández-Molina G; Valim V; Secco A; Atisha-Fregoso Y; Guerra E; Adrover M; Lage Santos AJ; Catalán-Pellet A
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):182-185. PubMed ID: 29745873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and withdrawal of immunosuppressors in primary Sjögren's syndrome.
    Torres-Ruiz J; Faz-Muñoz D; Hernández-Díaz N; Hernandez-Molina G
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):177-181. PubMed ID: 28421999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Main causes and risk factors for hospitalisation in patients with primary Sjögren's syndrome.
    Atisha-Fregoso Y; Rivera-Vicencio Y; Baños-Pelaez M; Hernández-Molina G
    Clin Exp Rheumatol; 2015; 33(5):721-5. PubMed ID: 26315557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperviscosity in primary Sjögren's syndrome: clinical implications.
    Hernández-Molina G; Bermúdez-Bermejo P
    Int J Rheum Dis; 2017 Jan; 20(1):84-89. PubMed ID: 26807556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EBV reactivation serological profile in primary Sjögren's syndrome: an underlying trigger of active articular involvement?
    Pasoto SG; Natalino RR; Chakkour HP; Viana Vdos S; Bueno C; Leon EP; Vendramini MB; Neto ML; Bonfa E
    Rheumatol Int; 2013 May; 33(5):1149-57. PubMed ID: 22955798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation rates and timing of antimalarial drugs in primary Sjögren's syndrome.
    Baldini C; Notarstefano C; Pepe P; Ferro F; Luciano N; Tani C; Talarico R; Mosca M
    Clin Exp Rheumatol; 2013; 31(1):160. PubMed ID: 23021087
    [No Abstract]   [Full Text] [Related]  

  • 7. Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.
    Quartuccio L; Gandolfo S; Zabotti A; Zandonella Callegher S; Fabro C; De Vita S
    Front Immunol; 2019; 10():1527. PubMed ID: 31354708
    [No Abstract]   [Full Text] [Related]  

  • 8. Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome.
    Yan S; Li M; Wang H; Yang X; Zhao J; Wang Q; Liu Y; Lai J; Tian Z; Song H; Zhao Y; Zeng X
    Int J Rheum Dis; 2018 May; 21(5):1068-1075. PubMed ID: 29624870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH; Ha YJ; Kang EH; Song YW; Scofield RH; Lee YJ
    Rheumatology (Oxford); 2021 Jun; 60(6):2714-2724. PubMed ID: 33188390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
    Demarchi J; Papasidero S; Medina MA; Klajn D; Chaparro Del Moral R; Rillo O; Martiré V; Crespo G; Secco A; Catalan Pellet A; Amitrano C; Crow C; Asnal C; Pucci P; Caeiro F; Benzanquen N; Pirola JP; Mayer M; Zazzetti F; Velez S; Barreira J; Tamborenea N; Santiago L; Raiti L
    Clin Rheumatol; 2017 Nov; 36(11):2455-2460. PubMed ID: 28913747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.
    Heus A; Arends S; Van Nimwegen JF; Stel AJ; Nossent GD; Bootsma H
    Scand J Rheumatol; 2020 Jan; 49(1):38-46. PubMed ID: 31556344
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics and risk factors for pulmonary arterial hypertension associated with primary Sjögren's syndrome: 15 new cases from a single center.
    Zhang N; Zhao Y; Wang H; Sun W; Chen M; Fan Q; Yang Z; Wei W
    Int J Rheum Dis; 2019 Sep; 22(9):1775-1781. PubMed ID: 31368254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined interventional sialendoscopy and intraductal steroid therapy for recurrent sialadenitis in Sjögren's syndrome: Results of a pilot monocentric trial.
    Capaccio P; Canzi P; Torretta S; Rossi V; Benazzo M; Bossi A; Vitali C; Cavagna L; Pignataro L
    Clin Otolaryngol; 2018 Feb; 43(1):96-102. PubMed ID: 28585263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical fatigue characterises patient experience of primary Sjögren's syndrome.
    Arends S; Meiners PM; Moerman RV; Kroese FG; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Clin Exp Rheumatol; 2017; 35(2):255-261. PubMed ID: 28032845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome.
    Wang ZZ; Zheng QS; Liu HX; Li LJ
    Front Immunol; 2021; 12():783246. PubMed ID: 34868062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study.
    Iwata N; Tomiita M; Kobayashi I; Inoue Y; Nonaka Y; Okamoto N; Umebayashi H; Hara R; Ito Y; Sato Y; Mori M
    Pediatr Rheumatol Online J; 2020 Sep; 18(1):73. PubMed ID: 32943063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.